Harm R. Van Tinteren

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 96 publications

Optimising combination therapy for paediatric, adolescent and young adult patients with non-rhabdomyosarcoma soft tissue sarcomas: The OCTOPUS platform trial.

Optimising combination therapy for paediatric, adolescent and young adult patients with non-rhabdomyosarcoma soft tissue sarcomas: The OCTOPUS platform trial.

Journal: Tumori

Published: July 31, 2026

A Harmonized International Database of More Than 10,000 Pediatric Renal Tumor Patients From 30 Years of SIOP-RTSG Studies.

A Harmonized International Database of More Than 10,000 Pediatric Renal Tumor Patients From 30 Years of SIOP-RTSG Studies.

Journal: JCO clinical cancer informatics

Published: June 23, 2026

Systematic Review: Prognostic Molecular Biomarkers in Wilms Tumors.

Systematic Review: Prognostic Molecular Biomarkers in Wilms Tumors.

Journal: JCO precision oncology

Published: May 18, 2026

Normal Tissue Complication Probability Estimation for Metabolic Syndrome in Survivors of the Dutch National Wilms Tumor Cohort: A DCCSS-LATER Study.

Normal Tissue Complication Probability Estimation for Metabolic Syndrome in Survivors of the Dutch National Wilms Tumor Cohort: A DCCSS-LATER Study.

Journal: International journal of radiation oncology, biology, physics

Published: May 01, 2026

Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study.

Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 13, 2026

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Journal: Trials

Published: February 13, 2026

Long-Term Locoregional Control and Pattern of Recurrences After Implementation of Highly Conformal Flank Target Volumes and Image-Guided Intensity Modulated Arc Therapy for Pediatric Wilms Tumors.

Long-Term Locoregional Control and Pattern of Recurrences After Implementation of Highly Conformal Flank Target Volumes and Image-Guided Intensity Modulated Arc Therapy for Pediatric Wilms Tumors.

Journal: International journal of radiation oncology, biology, physics

Published: December 21, 2025

Comedication that increase the risk of cisplatin-induced hearing loss in pediatric cancer patients: a narrative literature review and meta-analysis.

Comedication that increase the risk of cisplatin-induced hearing loss in pediatric cancer patients: a narrative literature review and meta-analysis.

Journal: Frontiers in oncology

Published: December 16, 2025

What shapes satisfaction with daily life participation? Insights into functional outcomes after pediatric bone sarcoma treatment.

What shapes satisfaction with daily life participation? Insights into functional outcomes after pediatric bone sarcoma treatment.

Journal: Archives of physical medicine and rehabilitation

Published: December 16, 2025

What Shapes Satisfaction With Daily Life Participation? Insights Into Functional Outcomes After Pediatric Bone Sarcoma Treatment.

What Shapes Satisfaction With Daily Life Participation? Insights Into Functional Outcomes After Pediatric Bone Sarcoma Treatment.

Journal: Archives of physical medicine and rehabilitation

Published: December 16, 2025

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: November 20, 2025

Characteristics and Survival of Patients With Wilms Tumor and Bone Metastases: A SIOP-RTSG 93-01, SIOP 2001, and UK-IMPORT Study.

Characteristics and Survival of Patients With Wilms Tumor and Bone Metastases: A SIOP-RTSG 93-01, SIOP 2001, and UK-IMPORT Study.

Journal: Pediatric blood & cancer

Published: November 12, 2025

Showing 1-12 of 96

Last Updated: 09/26/2026